Abstract Library

#4590 Association of SST5TMD4 and SST5TMD5 expression with metastasis and poor prognostic markers in gastroenteropancreatic neuroendocrine tumours

Introduction: The expression of the somatostatin receptor isoform SST5TMD4 is linked to poorer prognosis in somatotropinomas, as well as in breast and thyroid cancers, and it is notably overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Pedraza-Arevalo S

Authors: Pedraza-Arévalo S, Díaz-Pérez J, Garcia-Carbonero R, Villabona C, Capdevila J,

Keywords: GEP-NET, somatostatin, truncated receptor, metastasis,

#4583 Improved assessment of gene rearrangements by targeting non-coding DNA regions in patients diagnosed with pancreatic neuroendocrine neoplasms

Introduction: Whole-genome sequencing projects documented the heterogeneity of pancreatic neuroendocrine neoplasms (PanNEN), while showing that few core pathways are consistently affected in their tumorigenesis. Comprehensive genomic profiling (CGP) of real-world cases is expected to recapitulate such heterogeneity for patient stratification and to inform precision therapy. While coding DNA is the focus of current CGP panels, the potential of targeting non-coding DNA (ncDNA) to improve structural variants detection has not been widely explored in this context.

Conference:

Presenting Author: Agnoletto C

Authors: Agnoletto C, Trevisani E, Borghesani M, Landoni L, Luchini C,

Keywords: neuroendocrine, non-coding DNAs, structural variants, clinical relevance, CGP panel,

#4573 Digestive neuroendocrine tumours: Patterns, pathways, and progress in personalised management

Introduction: Digestive neuroendocrine tumours (NETs), though rare, are increasingly diagnosed with their incidence rising. Histopathological examination is crucial for diagnosis and grading, based on cell differentiation and proliferation index. Often diagnosed late due to non-specific symptoms, these tumours may present with hormone hypersecretion. Updated classifications now allow better risk stratification and tailored treatments. Advances in imaging, particularly PETscans with somatostatin analogues have improved NET diagnosis and monitoring.

Conference:

Presenting Author: Bensetti Houari A

Authors: Bensetti Houari A, Remouche H, Belkharoubi K,

Keywords: Digestive neuroendocrine tumour, octreoscan, multidisciplinary approach,

#4531 The role of metabolism in neuroendocrine tumour cell models and patients

Introduction: It is recognised that the adipose tissue plays a major role in cancer through a metabolic coupling that supports tumour cell growth. Recent evidence suggests that altered metabolic pathways drive the development and influence the clinical outcomes of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Calabrese C

Authors: Calabrese C, Dellavalle S, Miserocchi G, Gabellone S, Spadazzi C,

Keywords: tumour metabolism, adipocytes, RNA-sequencing, GEP-NET,

#4415 MGMT-activated DUB3 stabilises Nrf2/NCOA4 to modulate apoptosis and ferroptosis, driving temozolomide resistance in pancreatic neuroendocrine tumours

Introduction: O6-methylguanine DNA methyltransferase (MGMT) is a key DNA repair enzyme that removes methyl groups from O(6)-alkylguanine in DNA, introduced by temozolomide (TMZ). Clinical studies in pancreatic neuroendocrine tumours (PanNETs) have confirmed its role in TMZ efficacy.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Chen R, Wang Y, Chen X,

Keywords: pancreatic neuroendocrine tumour, MGMT, temozolomide, ferroptosis,